{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:30:39Z","timestamp":1788395439317,"version":"build-2803163510"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>TKIs long-term treatment in CML may lead to persistent adverse events (AEs) that can promote relevant morbidity and mortality. Consequently, TKIs dose reduction is often used to prevent AEs. However, data on its impact on successful treatment-free remission (TFR) are quite scarce. We conducted a retrospective study on the outcome of CML subjects who discontinued low-dose TKIs from 54 Italian hematology centers participating in the Campus CML network. Overall, 1.785 of 5.108 (35.0%) regularly followed CML patients were treated with low-dose TKIs, more frequently due to relevant comorbidities or AEs (1.288, 72.2%). TFR was attempted in 248 (13.9%) subjects, all but three while in deep molecular response (DMR). After a median follow-up of 24.9\u00a0months, 172 (69.4%) patients were still in TFR. TFR outcome was not influenced by gender, Sokal\/ELTS risk scores, prior interferon, number and last type of TKI used prior to treatment cessation, DMR degree, reason for dose reduction or median TKIs duration. Conversely, TFR probability was significantly better in the absence of resistance to any prior TKI. In addition, patients with a longer DMR duration before TKI discontinuation (i.e., &amp;gt;6.8\u00a0years) and those with an e14a2 <jats:italic>BCR::ABL1<\/jats:italic> transcript type showed a trend towards prolonged TFR. It should also be emphasized that only 30.6% of our cases suffered from molecular relapse, less than reported during full-dose TKI treatment. The use of low-dose TKIs does not appear to affect the likelihood of achieving a DMR and thus trying a treatment withdrawal, but might even promote the TFR rate.<\/jats:p>","DOI":"10.3389\/fphar.2023.1154377","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T04:57:26Z","timestamp":1679547446000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study"],"prefix":"10.3389","volume":"14","author":[{"given":"A.","family":"Iurlo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Consonni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Miggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Binotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Rege-Cambrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tiribelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lunghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gozzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Pregno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Abruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Capodanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bucelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pizzuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Artuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Iezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Scalzulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"La Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Elena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. R.","family":"Scortechini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tafuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Latagliata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Caocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Luciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fo\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1182\/blood-2021-145411","article-title":"First interim analysis of the Italian dante study: De-escalation before treatment-free remission in patients with chronic myeloid leukemia treated with first-line nilotinib","volume":"138","author":"Breccia","year":"2021","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2217\/cpr.13.43","article-title":"Dasatinib for the treatment of chronic phase chronic myeloid leukemia","volume":"10","author":"Campbell","year":"2013","journal-title":"Clin. Pract."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1002\/cncr.32940","article-title":"Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study","volume":"126","author":"Cayssials","year":"2020","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): An interim analysis of a non-randomised, phase 2 trial","volume":"4","author":"Clark","year":"2017","journal-title":"Lancet Haematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): A non-randomised, phase 2 trial","volume":"6","author":"Clark","year":"2019","journal-title":"Lancet Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/bjh.17286","article-title":"TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia","volume":"193","author":"Claudiani","year":"2021","journal-title":"Br. J. Haematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11899-019-00524-w","article-title":"Is there a role for dose modification of TKI therapy in CML?","volume":"14","author":"Copland","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: Final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood.v122.21.257.257","article-title":"Nilotinib exerts direct pro-atherogenic and antiangiogenic effects on vascular endothelial cells: A potential explanation for drug-induced vasculopathy in CML","volume":"122","author":"Emir","year":"2013","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3324\/haematol.2018.205054","article-title":"Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice","volume":"104","author":"Fava","year":"2019","journal-title":"Haematologica"},{"key":"B13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41408-018-0125-0","article-title":"Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: Results from a nationwide series of 236 patients","volume":"8","author":"Hern\u00e1ndez-Boluda","year":"2018","journal-title":"Blood Cancer J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1182\/blood.v122.21.1503.1503","article-title":"Hypercholesterolemia in imatinib intolerant\/resistant CML-CP patients treated with nilotinib: A retrospective analysis","volume":"122","author":"Hiwase","year":"2013","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European leukemianet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): A multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/jcm10030515","article-title":"Dose optimization of tyrosine kinase inhibitors in chronic myeloid leukemia: A new therapeutic challenge","volume":"10","author":"Iurlo","year":"2021","journal-title":"J. Clin. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"839915","DOI":"10.3389\/fonc.2022.839915","article-title":"Treatment-free remission in chronic myeloid leukemia patients treated with low-dose TKIs: A feasible option also in the real-life. A Campus CML study","volume":"12","author":"Iurlo","year":"2022","journal-title":"Front. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1002\/cam4.3778","article-title":"Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study","volume":"10","author":"Malagola","year":"2021","journal-title":"Cancer Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12185-020-02880-3","article-title":"Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors","volume":"112","author":"Okamoto","year":"2020","journal-title":"Int. J. Hematol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: Interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41571-020-0367-1","article-title":"Treatment-free remission in patients with chronic myeloid leukaemia","volume":"17","author":"Ross","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.1182\/blood-2013-01-480194","article-title":"Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia","volume":"121","author":"Russo","year":"2013","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"9614","DOI":"10.1182\/blood-2022-157700","article-title":"Treatment-free remission outcome in patients with chronic myeloid leukemia in chronic phase following one year of nilotinib de-escalation: 96-Week update of dante study","volume":"140","author":"Stagno","year":"2022","journal-title":"Blood"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1154377\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T04:57:29Z","timestamp":1679547449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1154377\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":24,"alternative-id":["10.3389\/fphar.2023.1154377"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1154377","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"article-number":"1154377"}}